Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
April 6th, 2022
The interaction of genetic susceptibility, mucosal immunity, and intestinal microecological environment is involved in the pathogenesis of inflammatory bowel disease (IBD). In this study, we applied fecal microbiota transplantation to IL-10 deficient mice and investigated its impact on colonic inflammation and heart function.
Three clinical experiments suggested that fecal microbiota transplantation carries the therapeutic potential for a number of human diseases. Further mechanistic studies will help bring FMT from bench to bedside. This method adopts oral gavage for the delivery route, allowing more precise volume delivery and the fast absorption.
It requires only moderate technical skills. Demonstrating the procedure will be Xioying Zhong, a senior research associate from our laboratory. Begin by preparing sterile paper towels, blunt end forceps, and 50 milliliter conical tubes.
Place some paper towels and forceps in separate autoclave bags and autoclave them at 180 degrees Celsius in dry heat for 30 minutes. Weigh the sterile conical tubes and write down their weight on the tubes. Turn on the biosafety cabinet in the animal room.
Take an autoclaved clean mouse cage without any bedding and place it in the biosafety cabinet. Remove the cover and the food rack and place them inside the cabinet. Place some sterile paper towels on the bottom of the cage, and place the metal rack back on top of the cage.
Identify age matched fecal donors and place the mouse cage in the biosafety cabinet. Open the cage and gently grab a donor mouse by the tail and place it on the metal rack on top of the clean cage. Place the cage cover on top of the rack and wait for the animal to defecate.
Collect the fecal pellets and put them in a sterile 50 milliliter conical tube. Pull the pellets by sex. Weigh the tube again and calculate the weight of the fecal pellets.
Prepare a sterile solution by adding 10%glycerol solution to normal saline. Add 10 milliliters of this solution to the conical tube for each gram of fecal pellets. Homogenize this mixture at a low speed three times for 30 seconds using a benchtop homogenizer inside a fume hood to resuspend the feces.
Filter the fecal suspension through two layers of sterile cotton gauze. Store the filtrate temporarily in a refrigerator for up to six hours, or package it into sterile cryogenic vials and store it in a minus 80 degree freezer. Thoroughly clean the homogenizer or blender following a standard procedure.
Thaw the frozen fecal suspension on ice if using frozen samples. Mix the thawed fecal suspension by vortexing. Transfer the fresh or thaw fecal suspension to one milliliter syringes.
Weigh the mice and choose the right gavage needle size and maximum dosage volume. Test the gavage needle by measuring the length from the tip of the mouse's nose to the bottom of the sternum. Fill the syringe with 10%glycerol in saline or fecal suspension and remove air bubbles inside the syringe and the needle.
Place one mouse cage in the biosafety cabinet. Remove the plastic cage cover and leave the metal rack in place. Open the metal rack with one hand.
Grab one mouse by the tail and put it on the metal rack. Hold the mouse by the tail with one hand and use the thumb and middle fingers of another hand to restrain the animal by grasping the skin over the shoulders. Gently extend the animal's head backward and hold the head in place with one hand.
Place the gavage needle on top of the tongue inside the mouth. Gently advance along the upper pallet until the needle reaches the esophagus. Pass the needle smoothly in one motion.
Once the needle is properly placed and verified, slowly administer the material by pushing the syringe attached to the needle. After dosing, gently pull the needle out. Mark the mouse and return it to its home cage.
Monitor the animal for five to 10 minutes by looking for signs of labored breathing or distress. Monitor the mice again between 12 to 24 hours after the fecal microbiota transplantation. Enzyme immunoassay revealed that B type natriuretic peptide was markedly elevated in the plasma of interleukin 10 deficient mice.
A healthy donor fecal microbiota transplantation significantly mitigated the increase in B type natriuretic peptide levels. Echocardiography detected a significant decrease in the left ventricle ejection fraction in the interleukin 10 deficient mice compared to the wild type mice. The decrease was significantly abrogated by fecal microbiota transplantation.
These findings suggest that healthy donor fecal microbiota transplantation mitigated colitis induced cardiac impairment. When attempting the protocol, choosing the right gavage needle is essential. Flexible plastic feeding tubes could be a better choice for beginners.
It is also important to practice animal handling before gavage.
View the full transcript and gain access to thousands of scientific videos
Overview
This study investigates the role of fecal microbiota transplantation (FMT) in IL-10 deficient mice, focusing on its effects on colonic inflammation and heart function. The research highlights the therapeutic potential of FMT for inflammatory bowel disease (IBD).
Key Study Components
Area of Science
- Neuroscience
- Gastroenterology
- Immunology
Background
- Inflammatory bowel disease (IBD) involves genetic susceptibility and mucosal immunity.
- The intestinal microecological environment plays a crucial role in IBD pathogenesis.
- Fecal microbiota transplantation has shown promise in treating various diseases.
- Mechanistic studies are essential for translating FMT to clinical settings.
Purpose of Study
- To explore the impact of FMT on colonic inflammation in IL-10 deficient mice.
- To assess the effects of FMT on heart function.
- To provide insights into the therapeutic potential of FMT for IBD.
Methods Used
- Fecal microbiota transplantation was performed using oral gavage.
- IL-10 deficient mice were utilized as the experimental model.
- Colonic inflammation and heart function were evaluated post-transplantation.
- Standard laboratory techniques were employed for analysis.
Main Results
- FMT significantly reduced colonic inflammation in IL-10 deficient mice.
- Improvements in heart function were observed following FMT.
- The study supports the therapeutic potential of FMT for IBD.
- Further research is needed to understand the underlying mechanisms.
Conclusions
- FMT shows promise as a treatment for inflammatory bowel disease.
- The findings highlight the importance of the intestinal microbiome in IBD.
- Future studies should focus on translating these findings to human applications.
Frequently Asked Questions
Executive Industry Relevance
Fecal microbiota transplantation (FMT) represents a mechanistic approach to modulate host-microbiota interactions in inflammatory bowel disease (IBD) models, offering a pathway to de-risk therapeutic hypotheses targeting gut-immune crosstalk. Demonstrating functional rescue of cardiac impairment in IL-10 deficient mice provides predictive confidence in FMT’s systemic effects beyond local colonic inflammation. This supports target validation strategies where microbiome modulation is evaluated for multi-organ impact in preclinical IBD programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of microbiota-host signaling pathways implicated in IBD pathogenesis and extraintestinal manifestations.
- Operational Value: Provides a standardized in vivo system to assess functional outcomes of microbiota modulation, such as cardiac biomarkers and ejection fraction.
- Predictive Value: Supports go/no-go decisions by linking microbiota changes to measurable physiological improvements in disease-relevant systems.
Screening & Assay Development
- Scientific Value: Generates quantifiable readouts (e.g., B-type natriuretic peptide levels, echocardiography) to evaluate microbiota-mediated physiological rescue.
- Operational Value: Establishes reproducible protocols for fecal sample collection, suspension preparation, and oral gavage delivery in murine models.
- Assay Readiness: Enables scalable evaluation of donor microbiota efficacy across genetic backgrounds or intervention conditions.
Translational & Preclinical Research
- Scientific Value: Demonstrates translational continuity from microbiota transfer to functional improvement in IBD-associated cardiomyopathy models.
- Operational Value: Supports longitudinal monitoring of disease modulation via non-invasive imaging and biomarker tracking post-FMT.
- Risk Mitigation: Facilitates mechanistic de-risking by linking microbial engraftment to downstream physiological endpoints.
Pipeline & Workflow Integration
FMT fits within the discovery-to-preclinical continuum as a tool for validating microbiome-targeted hypotheses, enabling assay development for functional screening, and supporting translational validation in disease-relevant systems prior to lead optimization.
- Discovery Biology: Tests mechanistic links between microbiota composition and host physiology in genetic IBD models.
- Screening: Delivers standardized microbiota suspensions for consistent evaluation of therapeutic microbiota preparations.
- Analytics: Generates quantitative biomarker and imaging data to compare intervention effects across experimental groups.
- Translational Research: Connects microbiota modulation to preclinical functional outcomes, supporting biomarker-aligned advancement decisions.
- Enterprise Reuse: Establishes a reusable platform for evaluating microbiota-based interventions across IBD and comorbidity models.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in microbiome-immune crosstalk by demonstrating rescue of cardiac dysfunction in IBD models.
- Operational Value: Ensures reproducibility through standardized fecal processing, gavage delivery, and post-transplant monitoring.
- Strategic Value: Improves preclinical prediction of systemic efficacy, reducing late-stage failure risk in microbiome-targeted programs.
- Portfolio Impact: Enables risk-adjusted prioritization of microbiota candidates based on multi-organ functional rescue.
Implementation Considerations
- Requires expertise in aseptic technique, animal handling, and oral gavage procedures.
- Depends on access to biosafety cabinets, homogenizers, and cardiac imaging or biomarker assay capabilities.
- Necessitates standardization across donor microbiota preparation, storage, and dosing volumes.
- Involves adaptation considerations for different mouse strains, ages, and disease severity models.
- Limited by variability in donor microbiota engraftment and host-specific responses, as noted in the protocol’s emphasis on proper technique and training.
